Immuneering Co. (NASDAQ:IMRX) Receives $12.80 Average Price Target from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have been given an average rating of “Hold” by the eight analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $12.20.

IMRX has been the subject of a number of analyst reports. Chardan Capital reissued a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research report on Wednesday, January 8th. Morgan Stanley cut shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of Immuneering in a report on Thursday.

Immuneering Price Performance

IMRX opened at $1.90 on Monday. The business has a fifty day moving average price of $2.05 and a 200 day moving average price of $1.89. Immuneering has a 12 month low of $1.00 and a 12 month high of $7.68. The stock has a market capitalization of $59.00 million, a price-to-earnings ratio of -0.96 and a beta of -0.36.

Institutional Trading of Immuneering

Institutional investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new stake in Immuneering during the 2nd quarter worth $492,000. Renaissance Technologies LLC purchased a new position in shares of Immuneering during the second quarter worth about $447,000. Tidemark LLC acquired a new stake in shares of Immuneering during the third quarter worth about $129,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Immuneering in the 2nd quarter valued at about $44,000. Finally, HighTower Advisors LLC boosted its position in shares of Immuneering by 33.7% in the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock valued at $157,000 after purchasing an additional 18,000 shares during the period. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.